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Abstract
Background: Programmed cell death-ligand 1 (PD-L1) may be a useful molecule for targeted immunotherapy.
Therefore, this meta-analysis aimed to investigate PD-L1 expression in breast cancer and its associations with
clinicopathological factors and outcomes, which may help determine whether PD-L1 expression is a useful
prognostic marker.
Methods: The Medline Ovid, Cochrane, PubMed, Google Scholar, and Web of Knowledge databases were searched
for studies that evaluated the prognostic or clinicopathological significance of PD-L1 expression in patients with
breast cancer, and reported at least one survival-related outcome.
Results: Six studies that included 7877 cases were selected for the analysis. Higher PD-L1 expression in all cells was
related to higher histological grade and lymph node metastasis. Higher PD-L1 expression in tumor cell was related
to larger tumor size, estrogen receptor negativity, progesterone receptor negativity, human epidermal growth factor
type-2 positivity, and triple-negative breast cancer. PD-L1 positivity in all cells was associated with poorer disease-free
survival, although it was not significantly associated with overall survival.
Conclusion: The present meta-analysis revealed that cases of breast cancer with PD-L1 positivity in all cells exhibited
higher histological grades, lymph node metastasis, and poorer disease-free survival. Therefore, positive expression of
PD-L1 may be a useful prognostic marker in breast cancer.
Keywords: PD-L1, Breast cancer, Prognosis, Meta-analysis
Background
Breast cancer is the most prevalent cancer among women,
and is the second leading cause of cancer-related deaths.
Molecular alterations are known to affect cancer occur-
rence and metastasis, which has led to the development of
hormonal therapy that targets the estrogen receptor (ER),
progesterone receptor (PR), or human epidermal growth
factor type 2 (HER-2). However, up to 20% of patients
with breast cancer experience disease progression and
death, which highlights the need for more effective
therapy [1].
The efficacy of immunotherapy is clear for immunogenic
tumors, such as malignant melanoma, non-small cell lung
cancer, and urothelial carcinoma. Furthermore, pro-
grammed cell death protein-1 (PD-1) and programmed cell
death-ligand 1 (PD-L1) may be useful molecules for tar-
geted immunotherapy. PD-1 is a co-inhibitory receptor
that belongs to the CD28/CTLA-4 family, and serves as a
negative regulator of the immune system by inhibiting the
function of T-cells in local tissues [2, 3]. PD-L1 (also
known as CD275 and B7-H1) is one of the PD-1 ligands
and is expressed in tumor cells. The interaction between
PD-L1 and PD-1 affects the antitumor immune response
and leads to tumor cell proliferation and metastasis [4, 5].
Although breast cancer has not been traditionally con-
sidered an immunogenic tumor, several studies have
suggested that patients with breast cancer exhibit a de-
fect in their immune response [6, 7]. Furthermore, cases of
triple-negative breast cancer (TNBC) or basal-like breast
cancer exhibit prominent infiltration of inflammatory cells,
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which suggests that an altered immune pathway plays a role
in tumorigenesis.
Several previous studies have evaluated the role of
PD-L1 as a prognostic marker. For example, Zhang et al.
evaluated patient with 12 types of epithelial-originated
cancers (e.g., breast cancer, cervical cancer, and renal cell
carcinoma), and found that PD-L1 positivity was associ-
ated with poorer overall survival (OS), compared to
PD-L1 negativity [8]. However, several other studies
have reported conflicting results [9, 10]. Moreover, regard-
ing the prognosis and PD-L1 immunohistochemical ex-
pression in breast cancer, only a data from a single center
is available, but those data also provided inconsistent
results [11–16]. Therefore, the present meta-analysis
aimed to investigate PD-L1 expression in breast cancer
and its associations with clinicopathological factors and
outcomes. This information may help determine whether
PD-L1 expression is a useful prognostic marker.
Methods
Literature search and selection criteria
On April 1, 2016, we searched several international data-
bases (Medline Ovid, Cochrane, PubMed, Google Scholar
and Web of Knowledge) using the following terms: ‘breast
cancer or breast carcinoma’, ‘PD-L1 or B7-H1’, and ‘progno-
sis’. Two independent researchers (JSK and HMK) reviewed
the search results. The inclusion criteria were: (1) studies
that evaluated the prognostic or clinicopathological signifi-
cance of PD-L1 expression in patients with breast cancer,
and reported at least one survival-related outcome (disease-
free survival [DFS], OS, or survival rates calculable using
the article’s data); (2) studies that used an anti-PD-L1 anti-
body for the immunohistochemistry; and (3) the specimens
were obtained using core needle biopsy or from the
postoperative specimen. The exclusion criteria were: (1)
studies that included patients who had received neoadju-
vant chemotherapy; (2) studies that included <50 cases;
and (3) studies that were not published in English. The
whole text was reviewed when the report fulfilled the in-
clusion criteria. In cases of disagreement, the reviewers
discussed the report and tried to reach a consensus. A
third researcher was consulted to provide a final opinion
in cases where a consensus could not be reached.
Data collection
Data extraction was performed according to the Cochrane
guidelines. The following variables were extracted for the
present meta-analysis: first author’s name, publication
year, patients’ nationality, number of patients, trial design,
mean age, clinicopathological parameters, PD-L1 positiv-
ity, study end-points (DFS and/or OS), and hazard ratios
(HR) and 95% confidence intervals (CI). All included
studies indicated that written informed consent had
been obtained from the included patients.
Statistical analysis
Q statistics from the chi-square test were used to evaluate
the presence of heterogeneity. However, as Q statistics are
not very powerful for evaluating heterogeneity, a higher
significance level is used to compensate for the low power
of the test [17]. The study effects were tested using a
random-effect model if the p-value from the Q statistic
was <0.1 and a fixed-effect model was used if the p-value
was ≥0.1. The I2 value was also used to evaluate hetero-
geneity; I2 is defined as 100% × ([Q – df] / Q), and ranges
between 0% (minor heterogeneity) to 100% (severe het-
erogeneity), where df = (the number of studies – 1).
The standard cut-off values for I2 are 25% (low), 50%
(moderate), and 75% (high) [18, 19]. For our analyses,
we reported relative risks (RRs) with 95% CIs for the
clinicopathological factors, and HRs with 95% CIs for
DFS and OS. Publication bias was assessed using a fun-
nel plot and Egger’s test. Begg’s test was not considered
for the analysis, as it has a very low power for detecting
bias in a small sample of studies [20]. All analyses were
performed using Comprehensive Meta-Analysis software
(version 2.0; Biostat Inc., Englewood, NJ) and R software
(version 3.2.2; http://www.r-project.org).
Results
Characteristics of the included studies
Thirty-two studies were identified from literature search
and 17 studies were excluded after title and abstract
reviewed. Nine studies were excluded for not meeting
the inclusion criteria. Finally, this meta-analysis included
6 studies and 7877 cases [11–16] (Fig. 1). The primary
characteristics of the included studies are presented in
Additional file 1. Table 1 and Table 2 show the basic
characteristics and clinicopathologic parameters of the
included studies. The reports were published between
2007 and 2016, and included patients from China, Brazil,
Fig. 1 Flow chart of the literature search and study selection
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England, Switzerland, Korea, and Saudi Arabia. In 3 of
the 6 studies, molecular genetic subtypes were analyzed.
However, among the 4578 cases included, 2490 cases
were luminal A type, 1001 cases were luminal B type,
260 cases were HER-2 type, and 827 cases were TNBC
type, showing a high heterogeneity.
Most of the studies used a cross-sectional design to
investigate PD-L1 expression in breast cancer, and uni-
variate analyses to evaluate DFS and OS. Every study
evaluated PD-L1 expression using immunohistochemistry,
and most studies used a polyclonal rabbit anti-PD-L1 anti-
body (Abcam, Cambridge, MA). Four studies evaluated
PD-L1 expression in tumor cells, 1 study evaluated im-
mune cells (lymphocytes), and one study evaluated both
tumor and immune cells. The positive cut-off values for
the immunohistochemistry varied between the studies,
with some studies evaluating the proportion of cells with
positive staining, and other studies using the H-score and
Allred score to evaluate both staining intensity and
staining percentage.
Associations of PD-L1 expression with clinicopathological
parameters
The included studies evaluated various clinicopathological
parameters, such as tumor size (≤2 cm vs. >2 cm), histo-
logical grade (1–2 vs. 3), lymph node metastasis, ER sta-
tus, PR status, HER-2 status, Ki-67 labeling index, and
molecular subtype (non-TNBC vs. TNBC). The studies all
evaluated different cell populations for positive PD-L1 ex-
pression. Therefore, we analyzed PD-L1 positivity in all
cells (tumor and immune cells) and in only tumor cells.
PD-L1 expression in tumor and immune cells
Higher PD-L1 expression in all cells was associated with
higher histological grade and lymph node metastasis.
The pooled RR for higher histological grade was 1.87
(95% CI: 1.49–2.36, Z = 5.32, p < 0.001; Fig. 2a), and the
fixed-effect model was used because of the low hetero-
geneity (I2 = 0%, p = 0.53). The pooled RR for lymph
node metastasis was 1.68 (95% CI: 0.97–2.91, Z = 1.85,
p = 0.06; Fig. 2b). Tumor size, ER status, PR status,
HER-2 status, Ki-67 labeling index, and molecular sub-
type (non-TNBC vs. TNBC) were not significantly asso-
ciated with PD-L1 expression in all cells.
PD-L1 expression in only tumor cells
Higher PD-L1 expression in only tumor cells was associ-
ated with larger tumor size (pooled RR: 1.89, 95% CI: 1.09–
3.27; Fig. 3a), ER negativity (pooled RR: 0.26, 95% CI: 0.09–
0.72; Fig. 3b), PR negativity (pooled RR: 0.27, 95% CI:
0.08–0.94; Fig. 3c), HER-2 positivity (pooled RR: 1.52,
95% CI: 1.06–2.18; Fig. 3d), and TNBC (pooled RR: 4.61,
95% CI: 1.08–19.63; Fig. 3e). Most variables were assessed
using a random-effect model, although a fixed-effect
model was used for HER-2 status because of its low
heterogeneity (I2 = 0%, p = 0.80). Histological grade,
lymph node metastasis, and Ki-67 labeling index were
not significantly associated with PD-L1 expression in
only tumor cells.
Effect of PD-L1 expression on survival (DFS and OS)
PD-L1 positivity in all cells was associated with poorer
DFS, compared to PD-L1 negativity, although there was
no significant difference in OS. The combined HR for
Fig. 2 Forest plots of studies that assessed the association between PD-L1 and clinicopathological factors in all cells. a Histological grade. b Lymph
node metastasis
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Fig. 3 Forest plots of studies that assessed the association between PD-L1 and clinicopathological factors in tumor cells. a Tumor size. b Estrogen
receptor status. c Progesterone receptor status. d Human epidermal growth factor receptor 2 status. e Molecular subtype
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DFS was 1.36 (95% CI: 1.03–1.79, p = 0.03; Fig. 4a), and
low heterogeneity was detected in the included studies
(P = 0.38, I2 = 0%). The combined HR for OS was 1.908
(95% CI: 0.91–4.00, p = 0.09; Fig. 4b), although significant
heterogeneity was detected in the included studies
(p < 0.001, I2 = 89%). When we re-performed the analysis
after excluding the study by Baptista et al. [11], the com-
bined HR for OS was 2.93 (95% CI: 1.69–5.09, p < 0.001)
and significant heterogeneity was detected in the included
studies (p = 0.005, I2 = 81%), although PD-L1 positivity now
exhibited a significant association with poorer OS (Fig. 4c).
Publication bias
The results from Egger’s test (p > 0.05) and the appear-
ance of the funnel plot revealed that publication bias
existed (Fig. 5).
Discussion
Previous research has highlighted the importance of the
tumor microenvironment, which includes non-tumor cells
with non-transformed elements (in close proximity to
tumor cells), immune cells (e.g., macrophages and lym-
phocytes), blood vessel cells, fibroblasts, myofibroblasts,
mesenchymal stem cells, adipocytes, and the extracellular
matrix. This information has led to the development of
immunotherapy as an option for cancer treatment. In this
context, PD-1 and PD-L1 play roles in a typical immune
pathway, and PD-L1 is expressed in 20–70% of patients
with lung cancer [4, 21–24], urinary bladder cancer [25],
malignant melanoma [26], and ovarian cancer [27].
Several studies have evaluated PD-L1 expression in
patients with breast cancer, although their conflicting
results necessitated a meta-analysis. Therefore, the present
Fig. 4 Forest plots of studies that assessed the association between PD-L1 and survival outcome in all breast carcinoma cells. a Disease-free survival.
b Overall survival. c Overall survival without one study (Baptista et al. 2016, reference [11])
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meta-analysis aimed to evaluate the clinicopathological
and prognostic significance of PD-L1 expression in breast
cancer. Our results revealed that higher histological grade
and lymph node metastasis were associated with higher
PD-L1 expression in tumor and immune cells, and that
PD-L1 expression in only tumor cells was associated with
larger tumor size, higher histological grade, ER negativity,
PR negativity, HER-2 negativity, and TNBC. Previous
Fig. 5 Egger’s test and funnel plot results for all included studies. a Overall survival based on all cells (p = 0.17). b Disease free survival based on
all cells (p = 0.15)
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studies have referred to the relationship between higher
histological grade, lymph node metastasis, larger tumor
size, and PD-L1 positivity as the ‘immune escape’
phenomenon. In this context, cancer cells often express
tumor antigens that are identified by the host immune
system, which results in clearance. However, an insuffi-
cient immune response reduces the anti-tumor reaction in
most cases (the immune escape) [1, 16, 28, 29]. In breast
cancer, Fas-ligand-positive breast cancer cells induce the
apoptosis of Fas-positive activated lymphocytes, which also
results in immune escape [30]. Furthermore, activation of
the PD-1/PD-L1 pathway lyses activated T-lymphocytes,
which protects cancer cells from the host’s immune system
[1, 31–33]. These relationships could be partially respon-
sible for tumor development and progression, and are con-
sistent with the findings of the present study, which
revealed associations of poor prognosis with higher histo-
logical grade, lymph node metastasis, and larger tumor
size. Furthermore, previous studies have suggested that
there is a relationship between PD-L1 and TNBC, as
TNBC exhibits increased peri-tumoral infiltration of CD8+
T-cells. This finding indicates that an abnormal immune
pathway is involved in TNBC tumorigenesis, which
might be related to higher PD-L1 expression in antigen-
presenting cells [12, 34]. In addition, the present study
revealed that PD-L1 positivity was associated with
established predictors of a poor prognosis: ER negativity,
PR negativity, and HER-2 negativity. Therefore, although
the underlying mechanism remains elusive, the relationship
between PD-L1 positivity and tumor aggressiveness may be
related to the immune escape phenomenon. Nevertheless,
further studies are needed to evaluate this possibility.
In the present study, PD-L1 expression in tumor or
immune cells was associated with poorer DFS. Similarly,
Sabatier et al. evaluated the expression of PD-L1 mRNA
in 45 breast cancer cell lines and 5454 breast cancer
cases [1], and found that higher PD-L1 mRNA expres-
sion was associated with larger tumor size, higher histo-
logical grade, ER and PR negativity, HER-2 positivity,
high proliferation, and the basal and HER-2 subtypes
(known markers of a poor prognosis). These findings
suggest that PD-L1-positive cells are more invasive and
have an aggressive phenotype, compared to other cells.
In contrast, Baptista et al. found that PD-L1 positivity
was associated with good OS [11], although their study
included a larger proportion of ER-negative cases, com-
pared to previous studies. Furthermore, previous studies of
ER-negative breast cancer with PD-L1 positivity revealed a
better survival rate [1, 12], which may indicate that the
conflicting findings of Baptista et al. may be related to
their case selection. Moreover, when we re-performed
our analysis after excluding the results of Baptista et
al., the combined HR for OS was 2.93 (95% CI: 1.69–
5.09, p < 0.001) with significant heterogeneity in the
included studies (p = 0.005, I2 = 81%). Thus, it remains
possible that PD-L1 positivity is associated with poorer
OS (Fig. 4c).
In PD-L1-positive cancer, targeting PD-L1 may help
improve the antitumor immune response, and several
recent preclinical and clinical trials have evaluated PD-
L1-targeted therapy [21–23, 25, 35–37]. For example,
two anti-PD-L1 antibodies have been developed: BMS-
936559 [38] and MPDL3280A [22, 25]. BMS-936559
provided good efficacy in a study of various malignancies
[38], which included tumor regression and the prevention
of disease progression in non-small cell lung cancer, mel-
anoma, and renal cell carcinoma. Another study evaluated
patients with various advanced incurable cancers, and
found that MPDL3280A provided confirmed responses
(complete and partial response) in 18% of the patients
[22]. Therefore, it may be important to evaluate PD-L1
expression in tumor cells, and the simplest and most
convenient technique is immunohistochemistry using
formalin-fixed paraffin-embedded specimens and a mono-
clonal anti-PD-L1 antibody. The commercially available
monoclonal PD-L1 antibody clones are 28-8 [39], 22C3
[40], SP142 [22, 25], and E1L3N [41, 42]. In the present
study, PD-L1 expression in all cells was associated with
poorer DFS in breast cancer cases, which further high-
lights the possible therapeutic value of anti-PD-L1 therapy
for breast cancer.
The present study has several strengths and limitations.
The first strength is that, to the best of our knowledge,
this is the first meta-analysis of PD-L1 expression and
prognosis among patients with breast cancer. Second, we
only included six studies, although these studies included
a large patient population (7877 patients). Nevertheless,
our findings should be interpreted with caution, based on
their inherent limitations. First, there was strong publica-
tion bias among the included studies. This may have been
caused by the heterogeneity of clinicopathologic charac-
teristics, such as race, age, molecular genetic entities and
tumor size, which resulted in a smaller effect in the meta-
analysis. Second, as the clone and the manufacturer of the
PD-L1 antibody that was used among the studies were
different, this might have affected in different staining
patterns and sensitivity. In particular, most studies in-
cluded in this meta-analysis used rabbit anti-PD-L1
polyclonal antibodies (Abcam, Cambridge, MA). Com-
pared to monoclonal antibodies, polyclonal antibodies
have limitations that they could often show unspecific
binding, high background staining and lack of reprodu-
cibility. Therefore, the difference in antibodies that
were used might have influenced in the result of this
study. Third, the cell components that were evaluated
for PD-L1 staining and the thresholds that were used in
the interpretation of PD-L1 positivity were different.
Therefore, future studies are needed to prospectively
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evaluate a large group of patients using a standardized
assessment of PD-L1 staining, which may help validate
our findings.
Conclusions
Our meta-analysis revealed that PD-L1 positivity in tumor
or immune cells from patients with breast cancer was
significantly associated with higher histological grade,
lymph node metastasis, and poorer DFS. Therefore,
positive PD-L1 expression may be useful for predicting
prognosis among patients with breast cancer.
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